Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
A prospective, randomized safety and efficacy study of Certican® as add-on therapy against
CMV disease in renal transplant recipients
OBJECTIVES:
Primary Objective:
To demonstrate efficacy of Certican® as add-on therapy against CMV disease in comparison to
either valcyte® (valganciclovir) or cymevene® (ganciclovir) alone, evaluated by quantitative
measurement of CMV-DNA with PCR from the blood (qCMV-PCR)
Secondary Objectives:
To assess safety and tolerability of Certican® in patients with CMV- disease To study the
effects of Certican® treatment on quality of life